Lv11
20 积分 2026-03-01 加入
Risk factors for EBV reactivation and impact of graft composition following GVHD prophylaxis with rabbit ATG or PTCy
2小时前
求助中
Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein–Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial
1天前
已完结
Donor activating killer cell immunoglobulin‐like receptors genes correlated with Epstein–Barr virus reactivation after haploidentical haematopoietic stem cell transplantation
3天前
已完结
Epstein–Barr virus posttransplant lymphoproliferative disorder: update on management and outcomes
3天前
已完结
Rituximab for posttransplant lymphoproliferative disorder – therapeutic, preemptive, or prophylactic?
3天前
已完结
Prevalence, management, and new treatment modalities of EBV-DNA-emia and EBV-PTLD after allo-HCT: survey of Infectious Diseases Working Party EBMT
11天前
已完结
Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein–Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial
15天前
已完结
18F-FDG PET/CT for Evaluation of Post-Transplant Lymphoproliferative Disorder (PTLD)
16天前
已完结
Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphoma
3个月前
已完结
CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus
3个月前
已完结
皖公网安备34019202002308
